Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | EVP Chief R&D | March 04, 2026 | March 06, 2026 |
| SQZ Biotechnologies CoSQZ · Entity 112267 | Director | June 14, 2023 | June 15, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date March 04, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,693 |
Ending reported balance
After 2026-03-05 transaction · row 12
12 source rows · reconciled sequenceRow 1 · 2026-03-04 · Sale · Disposed 106 · Balance 23,300 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2026-03-04 · Sale · Disposed 102 · Balance 23,198 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2026-03-04 · Sale · Disposed 215 · Balance 22,983 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-03-04 · Sale · Disposed 289 · Balance 22,694 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2026-03-04 · Sale · Disposed 350 · Balance 22,344 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2026-03-04 · Sale · Disposed 767 · Balance 21,577 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 7 · 2026-03-04 · Sale · Disposed 272 · Balance 21,305 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 8 · 2026-03-04 · Sale · Disposed 208 · Balance 21,097 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 9 · 2026-03-05 · Sale · Disposed 654 · Balance 20,443 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.03 to $322.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 10 · 2026-03-05 · Sale · Disposed 740 · Balance 19,703 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.09 to $324.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 11 · 2026-03-05 · Sale · Disposed 510 · Balance 19,193 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.26 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 12 · 2026-03-05 · Sale · Disposed 500 · Balance 18,693 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.67 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 431 |
Reported balance
Holding disclosure · report date 2026-03-04 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 431 F15: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 250 |
Reported balance
Holding disclosure · report date 2026-03-04 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 250 F16: Represents shares held in trust, of which the Reporting Persons spouse is co-trustee. The Reporting Person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.
F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025.
F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.03 to $322.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.09 to $324.08. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.26 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.67 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F15: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
F16: Represents shares held in trust, of which the Reporting Persons spouse is co-trustee. The Reporting Person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
SQZ Biotechnologies Co
Report date June 14, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2033-06-13 | Direct | 39,875 |
Reported balance
After 2023-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 39,875 · Balance 39,875 F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 98 | $361.45 | $35,422.10 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 9 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,342 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $360.90 to $361.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 155 | $360.22 | $55,834.10 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 8 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,440 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $359.79 to $360.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 85 | $359.14 | $30,526.90 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 7 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,595 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $358.69 to $359.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 123 | $358.18 | $44,056.14 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 6 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,680 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $357.68 to $358.68. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 96 | $357.17 | $34,288.32 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 5 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,803 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.63 to $357.63. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 41 | $356.09 | $14,599.69 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 4 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,899 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.62 to $356.61. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 42 | $355.16 | $14,916.72 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 3 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,940 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $354.54 to $355.53. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 39 | $353.95 | $13,804.05 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 2 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,982 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $353.53 to $354.41. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 11, 2026 Filed Jan 14, 2026 21:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 3,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-26-000015 · edgardoc.xml · nonDerivative · entry 1 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,021 F1 · kind: On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting $2.5 billion in annual net product revenue in accordance with GAAP, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors on January 11, 2026. Read SEC document |
| October 03, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 215 | $454.37 | $97,689.55 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 19 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,221 F14 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on September 11, 2024. F19 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.25 to $454.76. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 03, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 417 | $453.51 | $189,113.67 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 18 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,436 F14 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on September 11, 2024. F18 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.94 to $453.75. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 03, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 898 | $451.76 | $405,680.48 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 17 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,853 F14 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on September 11, 2024. F17 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.50 to $452.43. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 03, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 810 | $450.63 | $365,010.30 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 16 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,751 F14 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on September 11, 2024. F16 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.47 to $451.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 03, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 682 | $449.99 | $306,893.18 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 15 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,561 F14 · kind: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on September 11, 2024. F15 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.37 to $450.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 3 | $457.64 | $1,372.92 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 14 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,243 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 147 | $457.43 | $67,242.21 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 13 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,246 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 73 | $455.82 | $33,274.86 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 12 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,393 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.42 to $456.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 244 | $454.84 | $110,980.96 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 11 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,466 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.38 to $455.34. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 329 | $453.77 | $149,290.33 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 10 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,710 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.37 to $454.37. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 668 | $452.69 | $302,396.92 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 9 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,039 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.33 to $453.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 332 | $451.86 | $150,017.52 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 8 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,707 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.31 to $452.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 541 | $450.81 | $243,888.21 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 7 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,039 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.29 to $451.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 249 | $449.79 | $111,997.71 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 6 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,580 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.26 to $450.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 180 | $448.77 | $80,778.60 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 5 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,829 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $448.25 to $449.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 56 | $447.92 | $25,083.52 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 4 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,009 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.21 to $448.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 115 | $446.53 | $51,350.95 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 3 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,065 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $446.19 to $447.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 2,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 2 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,180 F2 · kind: On March 1, 2024, the reporting person was granted a PSU under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study in a prevalent indication, as determined by the PC&C Committee on October 1, 2025. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:12 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 3,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000113 · edgardoc.xml · nonDerivative · entry 1 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,329 F1 · kind: On February 24, 2021, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of four specified performance measures. The shares reported were issued to the reporting person upon vesting of one-quarter of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study of an RNAi therapeutic in development to treat a prevalent disease, as determined by the People, Culture and Compensation (PC&C) Committee of the Issuer Board of Directors on October 1, 2025. Read SEC document |
| August 19, 2025 Filed Aug 19, 2025 21:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 45 | $461.74 | $20,778.30 |
DisclosureSEC source: 0001735276-25-000092 · edgardoc.xml · nonDerivative · entry 15 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,221 F11 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024. Read SEC document |
| August 19, 2025 Filed Aug 19, 2025 21:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 305 | $461.01 | $140,608.05 |
DisclosureSEC source: 0001735276-25-000092 · edgardoc.xml · nonDerivative · entry 14 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,266 F11 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024. F16 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $460.60 to $461.44. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 19, 2025 Filed Aug 19, 2025 21:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 260 | $459.59 | $119,493.40 |
DisclosureSEC source: 0001735276-25-000092 · edgardoc.xml · nonDerivative · entry 13 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,571 F11 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024. F15 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $459.20 to $460.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 19, 2025 Filed Aug 19, 2025 21:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 231 | $458.27 | $105,860.37 |
DisclosureSEC source: 0001735276-25-000092 · edgardoc.xml · nonDerivative · entry 12 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,831 F11 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024. F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $457.76 to $458.65. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 19, 2025 Filed Aug 19, 2025 21:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 338 | $457.26 | $154,553.88 |
DisclosureSEC source: 0001735276-25-000092 · edgardoc.xml · nonDerivative · entry 11 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,062 F11 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024. F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $456.64 to $457.51. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 19, 2025 Filed Aug 19, 2025 21:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 276 | $455.41 | $125,693.16 |
DisclosureSEC source: 0001735276-25-000092 · edgardoc.xml · nonDerivative · entry 10 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,400 F11 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.94 to $455.77. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 12 | $455.82 | $5,469.84 |
DisclosureSEC source: 0001735276-25-000092 · edgardoc.xml · nonDerivative · entry 9 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,676 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.65 to $456.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 241 | $454.84 | $109,616.44 |
DisclosureSEC source: 0001735276-25-000092 · edgardoc.xml · nonDerivative · entry 8 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,688 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.58 to $455.55. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 543 | $454.04 | $246,543.72 |
DisclosureSEC source: 0001735276-25-000092 · edgardoc.xml · nonDerivative · entry 7 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,929 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.50 to $454.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 329 | $452.96 | $149,023.84 |
DisclosureSEC source: 0001735276-25-000092 · edgardoc.xml · nonDerivative · entry 6 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,472 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.49 to $453.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 103 | $451.99 | $46,554.97 |
DisclosureSEC source: 0001735276-25-000092 · edgardoc.xml · nonDerivative · entry 5 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,801 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.48 to $452.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 39 | $450.92 | $17,585.88 |
DisclosureSEC source: 0001735276-25-000092 · edgardoc.xml · nonDerivative · entry 4 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,904 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.42 to $451.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 90 | $449.92 | $40,492.80 |
DisclosureSEC source: 0001735276-25-000092 · edgardoc.xml · nonDerivative · entry 3 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,943 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.21 to $450.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 39 | $447.98 | $17,471.22 |
DisclosureSEC source: 0001735276-25-000092 · edgardoc.xml · nonDerivative · entry 2 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,033 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.53 to $448.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:28 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 2,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000092 · edgardoc.xml · nonDerivative · entry 1 Garg Pushkal · CIK 0001829252 · EVP Chief R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,072 F1 · kind: On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the achievement of a clinical milestone, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on August 15, 2025. Read SEC document |
| March 24, 2025 Filed Mar 25, 2025 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 5,445 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-25-000041 · edgardoc.xml · derivative · entry 6 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,445 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. F4 · derivative.exercise_date: This stock option was fully vested and exercisable as of December 20, 2020. Read SEC document |
| March 24, 2025 Filed Mar 25, 2025 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 5,445 | $300.00 | $1,633,500.00 |
DisclosureSEC source: 0001735276-25-000041 · edgardoc.xml · nonDerivative · entry 3 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,221 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. Read SEC document |
| March 24, 2025 Filed Mar 25, 2025 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 5,445 | $42.22 | $229,887.90 |
DisclosureSEC source: 0001735276-25-000041 · edgardoc.xml · nonDerivative · entry 2 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 20:10 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 4,321 | $285.00 | $1,231,485.00 |
DisclosureSEC source: 0001735276-25-000041 · edgardoc.xml · nonDerivative · entry 1 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,221 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 120 | $242.70 | $29,124.00 |
DisclosureSEC source: 0001735276-25-000032 · edgardoc.xml · nonDerivative · entry 15 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,542 F10 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. F17 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.46 to $242.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 198 | $241.60 | $47,836.80 |
DisclosureSEC source: 0001735276-25-000032 · edgardoc.xml · nonDerivative · entry 14 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,662 F10 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. F16 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.21 to $242.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 343 | $240.92 | $82,635.56 |
DisclosureSEC source: 0001735276-25-000032 · edgardoc.xml · nonDerivative · entry 13 Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,860 F10 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024. F15 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $240.18 to $241.17. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.